ACCELERATING THERAPEUTICS FOR PLEXIFORM AND CUTANEOUS NEUROFIBROMAS

Francis Collins Scholars Application Deadline: March 25, 2019

NTAP provides funding, resources, strategy and support to investigators around the world in order to develop effective therapies against plexiform and cutaneous neurofibromas.

News

Read the exciting and newly published study, that describes the activity of Selumetinib in NF1 associated plexiform neurofibromas. This study serves as an example of how NTAP addresses critical gaps in knowledge limiting the development of therapeutics for plexiform neurofibromas.  

Partner with NTAP

NTAP partners with key stakeholders in plexiform and cutaneous neurofibroma therapeutic research to ensure efforts are synergistic and have the greatest possible impact.

————————————————————————————————————————————————–

NTAP Announces the Annual 2018 Children’s Tumor Foundation NF Conference/18th European Neurofibromatosis Meeting

What We Do

The Neurofibromatosis Therapeutic Acceleration Program (NTAP) is focused exclusively on improving treatment options for people living with Neurofibromatosis type 1-related plexiform neurofibromas. With the goal of therapeutics always in mind, initiatives span research that probes the basic aspects of tumorgenesis through clinical investigations of drugs that have the highest likelihood of having a positive impact for patients. NTAP’s approach is defined by (1) intense collaboration both within and outside of the neurofibromatosis research community and (2) ongoing critical assessment of the existing needs and opportunities for developing effective plexiform neurofibroma therapeutics.